TCA cycle intermediate supplement

Calcium AKG (Alpha-Ketoglutarate)

Calcium AKG has no half-life reported in the papers read; the app lists about 3 hours, and the human data read are two uncontrolled reports, an analysis of 42 people and a survey cohort of 4260.1,3

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Calcium AKG (Alpha-Ketoglutarate) after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.

Drawn from the half-life in the app's model, ~3 h. The model's figures

Calcium AKG is the calcium salt of alpha-ketoglutarate, which Asadi Shahmirzadi and colleagues call "a key metabolite in the tricarboxylic acid (TCA) cycle".2 The app files it as a supplement in the TCA cycle intermediate group, lists it by the abbreviation Ca-AKG and also as Rejuvant, and grades its evidence as emerging. The human evidence read for this entry is uncontrolled: a retrospective analysis of 42 users of a Rejuvant product (Demidenko and colleagues, Aging, 2021) and a cross-sectional survey cohort of 4260 people (Pabis and colleagues, Aging Cell, 2026), whose longitudinal subset of Rejuvant users was 26 people.1,3 Neither was a placebo-controlled trial.1,3 Several of the authors have ties to Ponce de Leon Health (PDL Health), described in one paper as the producer of Rejuvant, and the mouse study was partly supported by that company.1,2,3 Randomised placebo-controlled trials are registered, including a Singapore trial (NCT05706389) listed as active, not recruiting, with no results reported in the papers read.7

Alpha-ketoglutarate is an intermediate in the TCA cycle, and a 2026 review states that it "serves as the metabolite for DNA and histone-modifying enzymes, enabling it to control the cells' epigenetic signature".4 The same review describes roles in nitrogen metabolism, including transamination of glutamate.4 Demidenko and colleagues note that AKG "is a known substrate for DNA demethylases", which they say "potentially demethylate DNA sites interrogated by TruAge".1 Whether a change in a methylation clock reflects a change in aging itself is not settled by these papers; the authors of the Rejuvant analysis themselves ask whether different measures of biological aging "measure the same, overlapping or completely different aspects of the aging process".1

Deeper analysis: Asadi Shahmirzadi and colleagues, mice, Cell Metabolism, 2020

This is an animal study and its results are not human results. C57BL/6 mice were switched to a diet containing CaAKG at 540 days of age, in two cohorts with "45 ± 2 females and 45 ± 2 males" each, "total of 182 animals".2 The diet contained 2% CaAKG by weight, and the authors report that it "increases survival in both cohorts of female mice".2 In the first female cohort, "median lifespan and survival (age at 90th percentile mortality) were significantly extended by 16.6% and 19.7% from inception of CaAKG feeding"; in the second the figures were 10.5% and 8%.2 In males, "improved survival for males was not significant in either cohort", although median lifespan was extended by 9.6% and 12.8%.2 Not every measure improved: the authors write that "Treated mice failed to perform better in a treadmill exhaustion test and showed no cardiac functional improvement".2 They also report that they "did not detect any decrease in mTORC1 signaling upon three months of CaAKG treatment".2 The authors propose that "induction of IL-10 by AKG treatment can be a potential mechanism for suppression of chronic inflammation", and state that this mechanism "is absent in male animals".2 Their stated limitations include that "the control diet lacked calcium" and that plasma AKG was not measured: "we did not quantify this in our study".2 On funding and ties, the paper states support from the Weldon Foundation and Ponce de Leon Health, NIH grants, and that several authors are shareholders in Ponce de Leon Health and "named inventors on a preliminary patent application related to this discovery".2

A multi-site mouse study that did not replicate a lifespan effect

Korstanje and colleagues for the Interventions Testing Program (GeroScience, 2026) tested alpha-ketoglutarate starting at 7 months in UM-HET3 mice at three sites, and the report states that "none of the tested compounds significantly increased lifespan in male or female mice".5 In males the table lists a control median of 813 days (n 300) and 841 days with alpha-ketoglutarate (n 153; +3.44%, log-rank p 0.429); in females it lists a control median of 903 days (n 272) and 889 days with alpha-ketoglutarate (n 132; log-rank p 0.228).5 The same paper recalls that the program "did not find an increase in lifespan when starting AKG at 18 months of age", and the table lists the compound as alpha-ketoglutarate without naming the calcium salt.5 The work was "funded in part by NIA grants" and the authors declare no competing interests.5

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 h
Bioavailability
80%
Typical dose
1000–3000 mg/day
Route
Oral
Time to peak
~1.5 h

The second column of the table holds the app's own figures, shown beside what the papers and registry entries read report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~3 hNone of the papers or registry entries read reports a half-life for calcium AKG or alpha-ketoglutarate in people
Bioavailability80%A 2026 review states that "reliable information on the level of enhancement of AKG bioavailability for each of the formulations is currently unavailable"4
Time to peak~1.5 hNone reported in the papers or registry entries read

The one human pharmacokinetic paper identified in that search concerned a different compound, L-arginine alpha-ketoglutarate (4 g, 10 healthy men), and measured plasma arginine, not alpha-ketoglutarate.6 Its result for that compound cannot be read as a result for calcium AKG.6 The Rejuvant products in the two human reports read were sustained, timed or delayed-release forms, so a half-life of the plain salt would not necessarily describe them.1,3

4

Human studies

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Demidenko and colleagues, Aging 20211Retrospective, uncontrolled analysis of customers' saliva methylation tests, compared with each person's own baseline test; not placebo controlled142 self-reported healthy people (14 women, 28 men), mean chronological age about 631Rejuvant (sustained-release CaAKG plus vitamin A for men or vitamin D for women), two tablets a day, 4 to 10 months, average 71Whole-cohort difference in means of 7.96 years in TruAge biological age (p-value 6.538x10-12, one-sided paired test); mean change 8.44 years in men and 6.98 years in women; 2 people (1 man, 1 woman) showed a slight increase; no adverse-event data in the text read1
Pabis and colleagues, Aging Cell 20263Cross-sectional survey cohort with a longitudinal subset; observational34260 purchasers of a saliva epigenetic test; 143 self-declared delayed-release Ca-AKG (Rejuvant) users3Dose and frequency not reported; self-reported use3Rejuvant use associated with an average 1.8-year lower Age Residual; regular AKG showed a smaller, non-significant difference; no significant improvement in the longitudinal analysis of 26 users3
ABLE, National University of Singapore, NCT057063897Randomised, quadruple-masked, placebo-controlled; registry entry7120 planned (estimated); middle-aged adults in Singapore7Ca-AKG or placebo, 500 mg pills, 1 g a day stated in the description, 6 months plus 3 months follow-up7Status active, not recruiting; primary outcome is change in blood DNA methylation clock; no results in the entry read7
OAK AGE, Stanford University, NCT072697048Open-label, single-arm, early phase 1; registry entry817 patients with age-related eye disease (actual enrolment)82 g/day calcium AKG, twice daily, 7 days before cataract surgery8Status completed; primary outcome is the change in aqueous humor aKG level; no results in the entry read8
AEGIS, National University Hospital Singapore, NCT070311289Randomised, quadruple-masked, placebo-controlled; registry entry9250 planned patients having coronary artery bypass grafting9AKG 1 g a day or placebo tablets, orally9Status recruiting; no results in the entry read9
AgelessRx, NCT07475546, a blend containing AKG10Randomised, no masking, multi-intervention pilot; registry entry1026 enrolled10A proprietary seven-compound blend including alpha-ketoglutarate, given alongside other agents10Status completed; the entry read reports no AKG-only comparison, so no result can be assigned to AKG10

Deeper analysis: Demidenko and colleagues, Aging, 2021

Demidenko and colleagues, from TruMe Inc. (Alameda, California), the National University of Singapore and Ponce de Leon Health, analysed customers who had two saliva DNA methylation tests, one before starting Rejuvant and one 4 to 10 months later.1 Participants "reported good or excellent health status without any chronic medical conditions", and 28 of 42 were men.1 The report states a "fixed dose of two tablets per day" and that "each dose contained 1 gram of Calcium Alpha-Ketoglutarate"; it does not say in that sentence whether a dose means a tablet.1 Although participants "were advised to use the treatment for 4 to 6 months", durations varied from 4 to 10 months.1 In the whole cohort the mean gap between biological and chronological age moved from 0.35 years younger at baseline to 8.31 years younger, a difference in means of 7.96 years (p-value of 6.538x10-12, one-sided paired test).1 A subset of 13 people who reported no change in diet, drinking, other supplements, sleep or exercise showed a difference in means of 7.69 years (p-value of 7.263x10-5).1 The results table also lists minimum changes in biological age of -1.86 (men) and -0.41 (women) and maximums of 22.7 and 14.09.1 The text states that only 2 individuals (1 man and 1 woman) showed a slight increase in biological age.1 The size of the change was larger in people with higher chronological age and in those biologically older than their chronological age, and "duration of the treatment is not correlated with the magnitude of the effect".1 The TruAge test is described as proprietary, based on 9 CpG sites in 3 genes read by Sanger sequencing, and its comparison with other clocks is described as "unpublished".1 The authors state the main limitation: "Primarily, it is not placebo controlled", add that the sample was limited and no clinical markers of aging were collected, and conclude that "Future randomized clinical trials will be required to confirm the findings presented here".1 They also write that they "did not measure whether the benefits in biological age are lost if the supplement is discontinued".1 Funding: the data came from Rejuvant users via Ponce de Leon Health and TruMe Labs, and the National University of Singapore "provided funding support" for the statistical analysis.1 The conflict statement says TruMe has a customer service agreement for testing Ponce de Leon Health customers taking Rejuvant, and that one author "is a scientific consultant and Board member for Ponce de Leon Health".1 The report does not give adverse-event or discontinuation figures in the text read.1

Deeper analysis: Pabis and colleagues, Aging Cell, 2026

Pabis and colleagues (National University of Singapore) analysed 4260 purchasers of a saliva-based epigenetic test who completed supplement questionnaires, using "a proprietary 9-CpG clock with a mean absolute error of 5.4 years".3 They tested 84 supplements; Rejuvant, a delayed-release calcium AKG with vitamin A or D3, was "associated with an average 1.8-year lower Age Residual", and the difference "remained significant in models adjusted for age, sex, smoking, health status and additional covariates".3 After matching, "dAKG users had a 1.27 years lower Age Residual compared to matched" non-users (p < 0.01).3 Null and secondary results: participants taking regular AKG "showed a much smaller and statistically insignificant benefit", and in the longitudinal subset dAKG "did not lead to a significant improvement" (26 users by survey).3 Among 294 people on a dAKG subscription the odds ratio for improvement was 1.37 (p = 0.045), but the result "became" non-significant "after correcting for baseline Age Residual and regression to the mean".3 In the cross-sectional comparison, the authors found that dAKG subscribers had an Age Residual comparable to non-users.3 The authors' limitations include that "Since the cohort is based on a convenience sample, it is more difficult to exclude recruiting and healthy user bias, leading to residual confounding", that "Frequency and dose of supplements were not reported", and that they "cannot exclude healthy user and selection biases".3 Some Rejuvant buyers recruited through PDL Health received a free epigenetic test, which the authors say "could further contribute to confounding".3 Funding and ties: the funding statement reads "The authors have nothing to report", TruMe Labs "provided access to proprietary data but had no role in the interpretation of the data", one author is "a scientific advisor and board member of PDL Health, which produces Rejuvant", and the conflict statement reads "The authors declare no conflicts of interest".3 The authors write that their data are "consistent with the hypothesis" that dAKG and CoQ10 supplementation reduce biological age, and call the evidence "tentative".3

The app lists a typical range of 1000 to 3000 mg/day. No product label for calcium alpha-ketoglutarate alone was identified in the DailyMed search run, so the table lists doses from studies and registry entries only.

Table 5.1Doses reported in studies and on labels7 rows
SourceDose, form and lengthReference
Demidenko 2021, 42 peopleRejuvant, "a fixed dose of two tablets per day"; "1 gram of Calcium Alpha-Ketoglutarate" per dose; timed-release; 4 to 10 months1
ABLE registry entryCa-AKG or placebo, pills of 500 mg, "half of daily dose", described as 1 g AKG; 6 months7
OAK AGE registry entry, 17 patients2 g/day calcium AKG orally, twice daily, 7 days8
AEGIS registry entryAKG tablets, 1 g once a day, orally; placebo tablets of 1 g9
Mouse study, Asadi Shahmirzadi 2020 (mice, not people)2% CaAKG by weight in the diet, from 18 months of age2
Mouse study, Korstanje 2026 (mice, not people)Alpha-ketoglutarate in feed from 7 months: target 20,000 ppm, achieved 3,262 ppm5
Campbell 2006, L-arginine AKG (a different compound), 35 men4 g three times a day (12 g daily), 8 weeks6

In the Rejuvant analysis and the survey cohort, the text read gives no adverse-event rates, and the survey cohort states that dose and frequency of supplements "were not reported".3 In the mouse study the authors "did not detect any significant adverse changes with CaAKG treatment", and "the only phenotypes that had a higher incidence in AKG-treated animals were cataracts and corneal opacity, although neither reached statistical significance".2 For L-arginine alpha-ketoglutarate, a different compound, 12 g daily for 8 weeks in 20 men, the authors concluded that it "appeared to be safe and well tolerated".6

7

Bloodwork and markers

The app lists no markers to monitor for calcium AKG. The ABLE registry entry lists secondary outcomes that include a complete blood count, immune parameters, renal function, glucose and insulin, from baseline to 6 months.7 The Rejuvant analysis measured a DNA methylation age from saliva; the authors say they "were unable to collect other kinds of data relevant to aging, for instance clinical markers of aging and disease".1

8

Regulatory and anti-doping status

A DailyMed search for "alpha-ketoglutarate" on 16 November 2026 returned three labels, all sprays listing ornithine alpha-ketoglutarate among several ingredients, and none for calcium alpha-ketoglutarate alone. The Stanford and Singapore registry entries differ in regulatory classification: the Stanford entry marks the study as FDA-regulated drug, and the ABLE entry marks it as not.8,7 The ABLE registry entry also describes alpha-ketoglutarate as "a generally regarded as safe (GRAS) micronutrient".7 The status of calcium alpha-ketoglutarate on the WADA Prohibited List was not established from the sources read.

No half-life, time to peak or bioavailability for calcium alpha-ketoglutarate in people was identified in the PubMed searches run, so the app's figures of about 3 hours, 80% and about 1.5 hours have no reported figure beside them here. No published results of a randomised, placebo-controlled trial of calcium AKG in people were identified in the PubMed and ClinicalTrials.gov searches run; the registered ABLE trial (Ca-AKG) and the AEGIS trial (described as AKG, without naming the salt) list no results in the entries read.7,9 The app's note describes a single open-label trial on a TruDiagnostic clock; the paper read describes a retrospective analysis of customers' tests with the proprietary TruAge test, from TruMe.1 Whether methylation-clock changes track health outcomes, whether any change persists after stopping, and what longer or higher-dose use does are not answered; the Rejuvant authors note "very little data on longer term use of Rejuvant® or higher doses".1 Mouse results disagree between a single-site study with a positive result in females and a three-site program that reported no lifespan effect.2,5 Differences between the calcium salt, other salts and delayed-release products are not compared head to head in the papers read; the review states that "A neck-to-neck comparison of the potential benefits and effectiveness for each of these chemical forms is not yet available".4

What is the half-life of calcium AKG?

None of the papers or registry entries read reports a half-life for calcium AKG in people, and the app lists about 3 hours. The study of a different compound, L-arginine alpha-ketoglutarate, measured plasma arginine and not alpha-ketoglutarate.6

How long does calcium AKG take to reach its peak level?

No time to peak is reported in the papers or registry entries read, and the app lists about 1.5 hours.

What is the bioavailability of calcium AKG?

A 2026 review states that reliable information on the enhancement of AKG bioavailability for each formulation is unavailable, and the app lists 80%.4

Did calcium AKG lower biological age by 8 years in a study?

The Rejuvant analysis by Demidenko and colleagues, of a formulation that combined sustained-release CaAKG with vitamin A or vitamin D, reported a difference in means of 7.96 years in 42 people over an average of 7 months, without a placebo group.1 The survey cohort of Pabis and colleagues reported a 1.8-year lower Age Residual for Rejuvant use, and no significant improvement in its longitudinal analysis.3

Has calcium AKG been tested in a placebo-controlled trial in people?

A placebo-controlled trial of Ca-AKG is registered (ABLE, NCT05706389), as is a placebo-controlled trial of AKG without a named salt (AEGIS, NCT07031128), but no published results were identified in the searches run.7,9

Does calcium AKG extend lifespan in mice?

Asadi Shahmirzadi and colleagues reported lifespan extension in female C57BL/6 mice fed 2% CaAKG, with survival not significantly improved in males.2 The Interventions Testing Program reported that alpha-ketoglutarate started at 7 months did not significantly increase lifespan in male or female UM-HET3 mice.5

Is calcium AKG approved by the FDA?

A DailyMed search on 16 November 2026 identified no label for calcium alpha-ketoglutarate alone.

Is calcium AKG banned by WADA?

The sources read do not state its status on the WADA Prohibited List.

What side effects have been reported for calcium AKG?

The Rejuvant analysis and the survey cohort give no adverse-event rates in the text read.1,3 In mice, the authors reported no significant adverse changes, with cataracts and corneal opacity more frequent in treated animals but not significantly so.2

12

References

  1. Demidenko O, et al. Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY) 2021. PMID 34847066
  2. Asadi Shahmirzadi A, et al. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. Cell Metab 2020. PMID 32877690
  3. Pabis K, et al. Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals. Aging Cell 2026. PMID 42166733
  4. Devulapalli V, et al. Alpha-Ketoglutarate: A Metabolic Regulator of Cellular Homeostasis and Pathophysiology. Biomedicines 2026. PMID 42072377
  5. Korstanje R, et al. Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. GeroScience 2026. PMID 41843349
  6. Campbell B, et al. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. Nutrition 2006. PMID 16928472
  7. National University of Singapore. Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults? ClinicalTrials.gov NCT05706389. NCT05706389
  8. Stanford University. Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease. ClinicalTrials.gov NCT07269704. NCT07269704
  9. National University Hospital, Singapore. Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS). ClinicalTrials.gov NCT07031128. NCT07031128
  10. AgelessRx. Combination Gerotherapeutic Interventions for Healthspan Improvement. ClinicalTrials.gov NCT07475546. NCT07475546